Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
Chemical Research in Toxicology|May 18, 2004
A proteomic investigation of drug-induced steatosis in rat liverGeorgina Meneses-Lorente, Paul C Guest, Jeffrey Lawrence, et al.
Biochemical Pharmacology|July 11, 2002
Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarrayFrançoise de Longueville, Dominic Surry, Georgina Meneses-Lorente, et al.
Chemical Research in Toxicology|September 16, 2003
An evaluation of a low-density DNA microarray using cytochrome P450 inducersGeorgina Meneses-Lorente, Françoise de Longueville, Sofia Dos Santos-Mendes, et al.
Molecular Cancer Therapeutics|April 15, 2018
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination TherapyAnnie Moisan, Francesca Michielin, Wolfgang Jacob, et al.
Investigational New Drugs|August 21, 2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)Georgina Meneses-Lorente, Stephen Fowler, Elena Guerini, et al.
Circulation Research|May 17, 2013
Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretionAndrew L Siebel, Alaina K Natoli, Felicia Y T Yap, et al.
British Journal of Clinical Pharmacology|March 14, 2019
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapyCandice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, et al.
Neuro-Oncology|April 18, 2013
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomasLindsay B Kilburn, Mehmet Kocak, Franziska Schaedeli Stark, et al.
Bioorganic & Medicinal Chemistry Letters|September 5, 2006
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonistsJason M Elliott, Robert W Carling, Mark Chambers, et al.
Pageof 4